Aktarım Tamamlandı — 

Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation

BACKGROUND: The ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) evaluated rivaroxaban (20/15 mg/d) versus warfarin in patients with atrial fibrillation. A separate trial, J‐ROCKE...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Am Heart Assoc
Asıl Yazarlar: Chan, Yi‐Hsin, Lee, Hsin‐Fu, Wang, Chun‐Li, Chang, Shang‐Hung, Yeh, Chih‐Hsin, Chao, Tze‐Fan, Yeh, Yung‐Hsin, Chen, Shih‐Ann, Kuo, Chi‐Tai
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6898830/
https://ncbi.nlm.nih.gov/pubmed/31623498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.013053
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller